Format

Send to

Choose Destination
J Control Release. 2011 Oct 30;155(2):200-10. doi: 10.1016/j.jconrel.2011.04.027. Epub 2011 May 5.

New pharmaceutical applications for macromolecular binders.

Author information

1
Faculty of Pharmacy, Université de Montréal, PO Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada. nicolas.bertrand@umontreal.ca

Abstract

Macromolecular binders consist of polymers, dendrimers, and oligomers with binding properties for endogenous or exogenous substrates. This field, at the frontier of host/guest chemistry and pharmacology, has met a renewed interest in the past decade due to the clinical success of several sequestrants, like sevelamer hydrochloride (Renagel®) or sugammadex (Bridion®). In many instances, multivalent binding by the macromolecular drugs can modify the properties of the substrate, and may prevent it from reaching its site of action and/or trigger a biological response. From small (e.g., ions) to larger substrates (e.g., bacteria and cells), this review presents the state-of-the-art of macromolecular binders and provides detailed illustrative examples of recent developments bearing much promise for future pharmaceutical applications.

PMID:
21571017
DOI:
10.1016/j.jconrel.2011.04.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center